| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Radiology, Academic Medical Center, Meibergdreef 9, G1-231, 1105
AZ Amsterdam, The Netherlands.
2 Department of Hematology, Academic Medical Center, 1105 AZ Amsterdam, The
Netherlands.
3 Department of Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The
Netherlands.
OBJECTIVE. The objective of our study was to determine the merit of the fat fraction of axial bone marrow measured by Dixon quantitative chemical shift imaging (Dixon QCSI) as a clinical parameter to quantitatively assess the extent of skeletal involvement in type 1 Gaucher's disease.
MATERIALS AND METHODS. Dixon QCSI was performed in 30 adult patients (age range, 18-69 years; mean, 39 years) with type 1 Gaucher's disease who were untreated. The relationship between the mean value of the fat fraction in vertebrae L3, L4, and L5 and the presence, absence, and severity of clinical bone complications (chronic bone pain, bone crisis, fracture, avascular necrosis, and joint replacement) as well as the conventional MR imaging of bone marrow involvement were studied. Also the relationship of fat fraction to sex, age, and other disease parameters (history of splenectomy, liver and spleen volume, plasma chitotriosidase, hemoglobin level, and platelet count) was evaluated. Our results were compared with the fat fraction of healthy volunteers.
RESULTS. The fat fraction measured in patients with Gaucher's disease ranged from 0.08 to 0.40 (mean, 0.20). Bone complications occurred primarily in patients with a fat fraction of less than 0.23. Univariate logistic regression analysis indicated that for every decrease of 0.1 of the fat fraction, the risk of bone complications increased 85% (p < 0.05). The fat fraction was correlated with liver size, but no correlation with other disease parameters was found. In the patient population, the fat fraction was significantly lower than in the healthy population (range, 0.27-0.55; mean, 0.37; p < 0.001).
CONCLUSION. The fat fraction of the lumbar spine when measured with Dixon QCSI is associated with the occurrence of bone complications. It may, therefore, be a clinically useful parameter.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. F. DeMayo, A. H. Haims, M. C. McRae, R. Yang, and P. K. Mistry Correlation of MRI-Based Bone Marrow Burden Score with Genotype and Spleen Status in Gaucher's Disease Am. J. Roentgenol., July 1, 2008; 191(1): 115 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Fost, C. J.M. van Noesel, J. M.F.G. Aerts, M. Maas, R. G. Poll, and C. E.M. Hollak Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy Haematologica, July 1, 2008; 93(7): 1119 - 1120. [Full Text] [PDF]
|
|
|
|
|
|
P. L. Robertson, M. Maas, and J. Goldblatt Semiquantitative Assessment of Skeletal Response to Enzyme Replacement Therapy for Gaucher's Disease Using the Bone Marrow Burden Score Am. J. Roentgenol., June 1, 2007; 188(6): 1521 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. de Fost, J. M.F.G. Aerts, J. E.M. Groener, M. Maas, E. M. Akkerman, M. G. Wiersma, and C. E.M. Hollak Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial Haematologica, February 1, 2007; 92(2): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. M. Hollak, M. d. Fost, J. M. F. G. Aerts, and S. vom Dahl Low-dose versus high-dose therapy for Gaucher disease: goals and markers Blood, January 1, 2007; 109(1): 387 - 387. [Full Text] [PDF]
|
|
|
|
|
|
A. Zimran, D. Elstein, and E. Beutler Response: Correlation between Gaucher disease clinical severity and surrogate markers is weak Blood, January 1, 2007; 109(1): 387 - 388. [Full Text] [PDF]
|
|
|
|
|
|
M. de Fost, C. E. M. Hollak, J. E. M. Groener, J. M. F. G. Aerts, M. Maas, L. W. Poll, M. G. Wiersma, D. Haussinger, S. Brett, N. Brill, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis Blood, August 1, 2006; 108(3): 830 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zimran, D. Elstein, and E. Beutler Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease Blood, August 1, 2006; 108(3): 802 - 803. [Full Text] [PDF]
|
|
|
|
|
|
R. G. Boot, M. Verhoek, M. de Fost, C. E. M. Hollak, M. Maas, B. Bleijlevens, M. J. van Breemen, M. van Meurs, L. A. Boven, J. D. Laman, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention Blood, January 1, 2004; 103(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mariani, M. Filocamo, F. Giona, G. Villa, A. Amendola, P. Erba, F. Buffoni, F. Copello, A. Pierini, F. Minichilli, et al. Severity of Bone Marrow Involvement in Patients with Gaucher's Disease Evaluated by Scintigraphy with 99mTc-Sestamibi J. Nucl. Med., August 1, 2003; 44(8): 1253 - 1262. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
